Personalized Treatment of Urogenital Cancers Depends on the Microbiome

Zealand University Hospital28 enrolled

Overview

This is a randomized controlled trial where patients undergoing surgical treatment for urogenital cancers will be randomized in a two arms study: surgical treatment + antibiotics OR surgical treatment + placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Microbial Disease

Interventions

Tigecycline 50 MGDRUG

Local instillation of drug directly to the tumour tissue

PlaceboOTHER

Local instillation of sterile water directly to the tumour tissue

Eligibility

Sex: ALLMin age: 40 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Biopsy verified diagnosis of urological cancer, localized disease Exclusion Criteria: * Hospitalization within three months of surgery * Antibiotics within three months of surgery * Infectious disease, including UTI's within three months of surgery * History of cancers of the genitourinary tract * Diabetes

Locations (1)

Zealand University Hospital

Roskilde, Denmark

RECRUITING

Outcomes

Primary Outcomes

recurrence rate after surgical treatment of tumour

Time frame: 5 years after treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.